FDA Approves Empagliflozin for Adults With Chronic Kidney Disease at Risk of Progression
Pharmacy Times
SEPTEMBER 22, 2023
Empagliflozin (Jardiance) demonstrated a 28% relative risk reduction, with an absolute risk reduction of 3.6% per patient-year at risk in the treatment of chronic kidney disease.
Let's personalize your content